Encompass Wealth Advisors’s Medtronic MDT Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q4
Sell
-2,449
Closed -$233K 107
2025
Q3
$233K Buy
2,449
+6
+0.2% +$552 0.08% 99
2025
Q2
$213K Hold
2,443
0.08% 100
2025
Q1
$220K Buy
+2,443
New +$219K 0.09% 93
2024
Q4
Sell
-8,543
Closed -$769K 119
2024
Q3
$769K Hold
8,543
0.19% 108
2024
Q2
$672K Hold
8,543
0.18% 109
2024
Q1
$745K Sell
8,543
-34
-0.4% -$2.9K 0.2% 104
2023
Q4
$707K Hold
8,577
0.21% 93
2023
Q3
$672K Buy
8,577
+6
+0.1% +$502 0.22% 86
2023
Q2
$755K Sell
8,571
-46
-0.5% -$3.96K 0.25% 80
2023
Q1
$695K Hold
8,617
0.24% 80
2022
Q4
$670K Buy
8,617
+28
+0.3% +$2.27K 0.24% 76
2022
Q3
$694K Buy
8,589
+2,700
+46% +$243K 0.26% 68
2022
Q2
$529K Sell
5,889
-68
-1% -$6.89K 0.19% 100
2022
Q1
$661K Buy
5,957
+18
+0.3% +$1.9K 0.17% 106
2021
Q4
$614K Buy
5,939
+46
+0.8% +$5.33K 0.15% 111
2021
Q3
$738K Sell
5,893
-1,000
-15% -$129K 0.19% 91
2021
Q2
$855K Hold
6,893
0.21% 91
2021
Q1
$885K Sell
6,893
-2,405
-26% -$282K 0.23% 85
2020
Q4
$1.09M Buy
+9,298
New +$1.02M 0.63% 36

Other funds holding MDT

Encompass Wealth Advisors's MDT Position: Q4 2025 in Review

Encompass Wealth Advisors sold out of Medtronic (MDT) in Q4 2025, closing a stake of 2,449 shares — an estimated $233K sold.

Encompass Wealth Advisors first reported a position in MDT in Q4 2020 and held it in 19 quarters. The position peaked at $1.09M in Q4 2020. 2,303 funds tracked by Wall St. Rank hold MDT as of Q4 2025.

  • Encompass Wealth Advisors reported no remaining Medtronic position as of Q4 2025 after selling out during the quarter.
  • Encompass Wealth Advisors sold 2,449 Medtronic shares in Q4 2025, an estimated $233K.
  • Encompass Wealth Advisors first reported a position in Medtronic in Q4 2020 and held it in 19 quarters.
  • Encompass Wealth Advisors's Medtronic position peaked at $1.09M in Q4 2020.
  • 2,303 funds tracked by Wall St. Rank held Medtronic as of Q4 2025.

Based on Encompass Wealth Advisors's 13F filing for Q4 2025, filed 22 Jan 2026.